Samsung Bioepis is a biopharmaceutical company, acquired by Samsung Biologics as a wholly owned subsidiary in Q2 2020, that is dedicated to unlocking the potential of biosimilar medicines and transforming the way biologic therapies are brought to patients. Since its establishment in 2012, the company has developed an expansive biosimilars portfolio, and has opened up access to life-changing and life-saving medicines in immunology and oncology, including being the first to secure European approval of three key biosimilars for autoimmune conditions.
Samsung Bioepis is expanding into new areas of unmet need in hematology, gastroenterology, and endocrinology, and is harnessing smart development processes for biosimilars to develop the next generation of novel biologics.